RegulationPriority Review (United States), Breakthrough Therapy (United States), PRIME (European Union), Accelerated assessment (European Union), Fast Track (United States)

Structure/Sequence

Sequence Code 9535613

Sequence Code 10051604

Sequence Code 10051610

Clinical Trials associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

NCT07467707

/ Not yet recruitingPhase 3

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

Start Date01 May 2026

Sponsor / Collaborator

Bavarian Nordic A/S

[+4]

NCT07003984

/ RecruitingPhase 3

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.

Start Date05 Jun 2025

Sponsor / Collaborator

Bavarian Nordic A/S

NCT06007183

/ Active, not recruitingPhase 3

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial CHIKV VLP vaccination.

Start Date30 Aug 2023

Sponsor / Collaborator

Bavarian Nordic A/S

100 Clinical Results associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

100 Translational Medicine associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

100 Patents (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

134

Literatures (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

01 Mar 2026·VACCINE

Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya

Review

Author: Schönfeld, Christian ; Grünewald, Thomas ; Branke, Lisa ; Kling, Kerstin ; Ramharter, Michael ; Falman, Annika ; Rothe, Camilla

BACKGROUND:

Infections with the chikungunya virus are increasingly reported due to many reasons including climate change. Two vaccines against chikungunya have recently been approved in Europe, the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. However, no systematic review of phase 3 clinical trial data has been published that summarizes the currently available evidence on the immunogenicity, tolerability, and safety of these vaccines. Therefore, these data were systematically analyzed by a working group of the German Standing Committee on Vaccination (STIKO) and the German Society for Tropical Medicine, Travel Medicine and Global Health (DTG).

METHODS:

We conducted a systematic review of the immunogenicity, tolerability and safety of Ixchiq and Vimkunya using Embase and PubMed (OVID) according to predefined PICO criteria, including placebo-controlled randomized control trials, cohort, and case-control studies. Risk of bias (RoB) was assessed with the RoB 2-tool. Additionally, post-marketing safety data were studied.

RESULTS:

Clinical efficacy data were not available. Instead, seropositivity rates above a predefined threshold served as a surrogate of protection. Both vaccines demonstrated strong immunogenicity with seroprotection rates for Ixchiq of >98% after 4 weeks, and for Vimkunya after 3 weeks of >97% in 12-59-year-olds and > 87% in ≥65-year-olds. In the pivotal studies, both vaccines showed also an acceptable safety profile. Post-marketing safety data showed a higher risk for serious adverse events in elderly patients for Ixchiq.

CONCLUSION:

In addition to mosquito protection and vector control, two vaccines with a good efficacy profile based on the surrogate marker of seroprotection are now available to prevent chikungunya. While both vaccines showed acceptable tolerability, the safety of vaccines must be continuously assessed based on further data from post-marketing surveillance of the respective populations.

01 Feb 2026·Current Opinion in Virology

A storm is born: immune activation and pathogenesis in arthritogenic alphavirus infections

Review

Author: Koo, Yong Qian ; Freppel, Wesley ; Herrero, Lara J

Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, and Mayaro viruses, are emerging global viruses responsible for causing arthralgia and chronic arthritis. Following mosquito-borne transmission, they quickly initiate infection in the skin, including in resident immune cells, and disseminate systemically into musculoskeletal tissues. The innate immune system responds rapidly through the activation of interferons, the production of inflammatory cytokines, and the recruitment of monocytes, macrophages, neutrophils, and dendritic cells, while the adaptive immune response, particularly virus-specific T and B cells, is critical for viral clearance. However, excessive immune activation can lead to both acute and chronic musculoskeletal pain through cytokine storm, tissue damage, and supporting immunopathology. Additionally, viral persistence and immune evasion may contribute to the development of chronic synovitis and cartilage degradation, leading to persistent joint pain. Despite recent advances, antiviral treatments remain unavailable, and to date, there is only one vaccine licensed (VIMKUNYA™ in 2025, against CHIKV), underscoring the urgent need for further research. This review explores the complex interplay between host immune responses and viral factors that lead from acute infection to chronic inflammation. Furthermore, it highlights key gaps in understanding viral persistence and immune evasion, and how to predict chronic diseases to improve therapeutic and preventive strategies against arthritogenic alphaviruses.

31 Dec 2025·Expert Review of Vaccines

Virus-like particles: a versatile and effective vaccine platform

Review

Author: Bachmann, Martin F. ; Lienert, Florian ; van Damme, Pierre ; Schwarz, Tino F.

INTRODUCTION:

Traditional live-attenuated or inactivated vaccines have limitations, including risks associated with uncontrolled replication, reduced immunogenicity, or production complexities. To address these issues, alternative platforms such as virus-like particles (VLPs) have been developed.

AREAS COVERED:

VLPs are self-assembling structures composed of viral proteins that mimic native viruses but are noninfectious. This review provides an overview of their structure, design and manufacture that make them an attractive platform for vaccine development. We then discuss the clinical development of some recently approved VLP vaccines and those widely used in immunization programs, summarizing the clinical trial data that underpins their efficacy and safety profiles. Additionally, we explore VLP vaccines in late-stage clinical development for respiratory syncytial virus and human metapneumovirus.

EXPERT OPINION:

VLPs are a versatile and promising platform for vaccine development. Their ability to mimic native viruses while eliminating the risks associated with live vaccines positions them as an attractive platform for vaccine design. Currently approved VLP vaccines demonstrate that they can provide effective protection against a wide range of diseases. Advances in VLP design and production are likely to lead to highly effective vaccines, significantly contributing to global immunization efforts.

News (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

16 Mar 2026

·www.pharmaceutical-technology.com

Bavarian Nordic and SII sign agreement for chikungunya vaccine production

Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries. The new arrangement builds upon the existing licence and manufacturing partnership between the two companies for the mpox vaccine. It replaces an earlier deal with Biological E. Both parties will also explore potential co-development opportunities as part of this extended collaboration. Bavarian Nordic’s president and CEO Paul Chaplin said: “We are pleased to strengthen our strategic partnership with Serum Institute of India. “By leveraging the strengths of both organisations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe.” The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for active immunisation against disease caused by the chikungunya virus in people aged 12 years and above. It is designed to trigger a strong seroresponse, with protective immunity beginning to develop as soon as one week following vaccination. As it does not contain viral genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a broad population demographic. Marketed as Vimkunya, CHIKV VLP has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US Food and Drug Administration (FDA) in 2025. Regulatory review is underway in Canada and Switzerland. In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, in the UK. The launch followed a significant increase in travel-related disease cases reported nationwide. The UK Health Security Agency (UKHSA) stated that incidences rose by 170% in August 2025 compared with the same period in 2024. The content above comes from the network. if any infringement, please contact us to modify.

VaccineDrug ApprovalLicense out/in

11 Mar 2026

·www.biospace.com

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries. Expanded collaboration provides future co-development opportunities. COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited. In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities. “ We are pleased to strengthen our strategic partnership with Serum Institute of India. B y leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President & CEO of Bavarian Nordic . About CHIKV VLP CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. CHIKV VLP (marketed as Vimkunya ® ) has been approved by the U.S. Food and Drug Administration, the European Commission and the U.K. Medicines & Healthcare products Regulatory Agency in 2025. Regulatory review of the vaccine is ongoing in Switzerland and Canada. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries 1 . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years 2 . In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide 3 . More than half of the reported cases and associated deaths were reported from Brazil 4 . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile 5 . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . About Serum Institute of India Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer, developing life-saving vaccines against diseases including polio, measles, meningitis, rotavirus, diphtheria, tetanus, malaria, HPV, pneumonia, and COVID-19, with a mission to make affordable vaccines accessible worldwide. Present across 170+ countries, including the U.S., the UK, and Europe, SII operates one of the largest multifunctional vaccine production facilities in Manjri, Pune, with an annual capacity of 4 billion doses, contributing to saving over 30 million lives over the years. For more information, visit . Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 1 World Health Organization (WHO). Chikungunya. 2 European Centre for Disease Prevention and Control. Chikungunya virus disease . . 3 European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview . . 4 Pan American Health Organization (PAHO). Chikungunya: analysis by country. 5 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

Drug ApprovalVaccineLicense out/in

23 Jan 2026

·www.globenewswire.com

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccinePotential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil. Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. The agreement is transfer price and royalty-based with no associated upfront or milestone payments. Eurofarma will be responsible for seeking and maintaining regulatory approval of the vaccine in exclusive territories, as well as sales and distribution costs. Bavarian Nordic will remain the manufacturer of the vaccine, which is made available to Eurofarma through a transfer price agreement. Pending discussions with the Brazilian Health Regulatory Agency, Anvisa, regulatory submission is expected to occur later in the first half of 2026, potentially supporting launch of the chikungunya vaccine in Brazil in the second half of 2027. “Following a successful launch of our chikungunya vaccine for travelers in the first Western markets in 2025, we are pleased to expand the commercial availability also for endemic populations through this first distribution agreement,” said Paul Chaplin, President & CEO of Bavarian Nordic. “Brazil remains severely impacted by chikungunya, representing half of all reported cases and related deaths worldwide. Together with Eurofarma, a local partner with strong regional presence, we continue our efforts to make a lasting impact on public health globally.” “Our partnership with Bavarian Nordic reinforces Eurofarma’s commitment to innovation and to expanding access to high‑quality healthcare. It builds on our strong capabilities to deliver high‑impact solutions for people in Brazil and across Latin America—so that everyone has the opportunity to live longer and better,” says João Siffert, Eurofarma’s Vice President of Innovation. While the agreement aims to significantly improve access to chikungunya vaccines in Brazil, it is not expected to have a material short- to medium-term financial impact on Bavarian Nordic. // About CHIKV VLPCHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. The vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 and the United Kingdom in May 2025 under the trade name VIMKUNYA®1. About chikungunyaChikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries2. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years3. In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide4. More than half of the reported cases and associated deaths were reported from Brazil5. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile6. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com. About EurofarmaFounded in 1972, Eurofarma covers key pharmaceutical segments and is the leader in medical prescriptions in Brazil. A Brazilian multinational company operating in 24 countries, with full coverage across Latin America and retail leadership in the region, the company also maintains operations in the United States and Africa, with more than 13,500 employees and 11 manufacturing facilities. In 2024, Eurofarma produced 600 million units. That same year, the company invested over USD 122 million in innovation projects and achieved net revenue exceeding USD 1.78 billion. For more information: www.eurofarma.com.br Contact investors:Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.comUS: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 1 Marketed as VIMKUNYA™ in the US. Marketed as VIMKUNYA® in EU and the United Kingdom. 2 World Health Organization (WHO). Chikungunya.https://www.who.int/news-room/fact-sheets/detail/chikungunya 3 European Centre for Disease Prevention and Control. Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease. 4 European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview. https://www.ecdc.europa.eu/en/chikungunya-monthly. 5 Pan American Health Organization (PAHO). Chikungunya: analysis by country. https://www.paho.org/en/arbo-portal/chikungunya-data-and-analysis/chikungunya-analysis-country 6 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

VaccineDrug Approval

100 Deals associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chikungunya Fever	United States	Bavarian Nordic A/S	14 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2025	Phase 2/3	Chikungunya Fever	3,141	CHIKV VLP vaccine	tfuypgvqir(jfvllxxwty) = zqmtwjsbvw radgnqipea (qeggismgbq ) View more	Positive	24 Oct 2025
				Placebo	onhmplaqhw(wdjwurqtjq) = aicaziiljb kcrwiwulnc (hixcpkotex )
NCT03992872 (Pubmed \| Lancet Microbe)	Phase 2	Alphavirus Infections	60	Previous alphavirus vaccine recipients	zplulzxtqf(txdsugcrlz) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events cgcfcmbfjb (txryzpgvoj )	Positive	01 Apr 2025
				Alphavirus vaccine-naive controls
NCT05072080 (FDA_CBER) Manual	Phase 3	Chikungunya Fever	-	VIMKUNYA	pxwilvhvex(pwxiuelzze) = mwqurquevt ptpycuvumc (mtgtsxhwbh, 1504.1 - 1695.6) View more	Positive	14 Feb 2025
				Placebo	pxwilvhvex(pwxiuelzze) = jjysouxoug ptpycuvumc (mtgtsxhwbh, 7.0 - 8.8) View more
NCT05349617 (FDA_CBER) Manual	Phase 3	Chikungunya Fever	-	VIMKUNYA	vngizpsjks(xdrnbkigzt) = erbjsubsmh lzdopjbaxq (mvpnfyjihg, 582.3 - 892.7) View more	Positive	14 Feb 2025
				Placebo	vngizpsjks(xdrnbkigzt) = yzpokucfbf lzdopjbaxq (mvpnfyjihg, 6.5 - 10.0) View more
NCT05349617 (CTgov)	Phase 3	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	ojuyrcdliu = rdhbyeaqae srzbegxuio (vrincjarlk, vdrnimnhyd - bipdbyhzmu) View more	-	13 Dec 2024
				Placebo (Group 2 - Placebo)	ojuyrcdliu = stylnhwbgl srzbegxuio (vrincjarlk, gmforqymsj - uyreryzpio) View more
NCT05072080 (CTgov)	Phase 3	Chikungunya Fever	3,258	CHIKV VLP/adjuvant (Group 1)	yzllzyoise = letahqwzce gtdwvubhfz (ooeuqnvfgg, bhmsndpewh - xlymjwtgup) View more	-	30 Aug 2024
				CHIKV VLP/adjuvant (Group 2)	yzllzyoise = bnpqeqwikj gtdwvubhfz (ooeuqnvfgg, efgiimvkro - xoqdyzcnhi) View more
NCT02562482 (phase 2, Pubmed \| Vaccine)	Phase 2	Chikungunya Fever focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	pjqgdhblxm(drtsvyobyd) = wczarsykrm vwkztdemzj (mduvhypvuo )	Positive	01 Oct 2023
				CHIKV VLP vaccine seronegative recipients	pjqgdhblxm(drtsvyobyd) = nqgabmnejh vwkztdemzj (mduvhypvuo )
NCT05065983 (CHIKV VLP, CTgov)	Phase 2	Chikungunya Fever	25	CHIKV VLP, adjuvanted	kkppojegem = xamadlxefr hwptqiwkdg (agivycvopd, kellgetrlt - wbpiucrkil) View more	-	28 Feb 2023
NCT03992872 (WRAIR, Biospace) Manual	Phase 2	Alphavirus Infections \| Chikungunya Fever	60	PXVX 0317	bxrrgsasnb(jtxnlmgxqh) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. aninqwxbrx (iljgmwlznu )	Positive	01 Nov 2022
NCT02562482 (Pubmed \| J Coll Physicians Surg Pak) Manual	Phase 2	Chikungunya Fever	400	PXVX-0317	bnvvdprgrb(yqvlwdwvqq) = fbbdoqvmcl ijapgysmaw (knmudgikbx ) View more	Positive	14 Apr 2020
				Placebo	bnvvdprgrb(yqvlwdwvqq) = bcsbqknlnh ijapgysmaw (knmudgikbx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chikungunya Vaccine, Recombinant (Bavarian Nordic)

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation